Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03079999 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Aspirin in Patients With Vestibular Schwannoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 18, 2025 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 2025 to Aug 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 300 to confirmed 97
    • Study sites: 6 to 5
    v20
  2. Re-verified, no change to tracked fieldsv19
  3. Site contacts updated at 6 of 6 sites
    • Collaborators: 2 to 1
    v18
  4. Site contacts updated at 6 of 6 sites
    • Collaborators reordered
    v17
  5. Study sites revised (6)v16
Show 14 earlier versionsHide 14 earlier versions
  1. Site details revised at 5 of 6 sitesv15
  2. Primary completion date: Sep 2022 to Sep 2025
    • Study completion date: Feb 2023 to Feb 2029
    v14
  3. Re-verified, no change to tracked fieldsv13
  4. Site contacts updated at 4 of 6 sitesv12
  5. Primary completion date: Feb 2021 to Sep 2022
    • Study completion date: Feb 2022 to Feb 2023
    • Study description expanded, about 178 words
    • Study sites revised (6)
    v11
  6. Site contacts updated at 1 of 6 sitesv10
  7. Study sites: 1 to 6v9
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2018 to Jun 11, 2018
    v8
  9. Start date: Apr 2018 to Jun 2018v7
  10. Start date: Jan 2018 to Apr 2018v6
  11. Start date: Oct 2017 to Jan 2018v5
  12. Start date: Aug 2017 to Oct 2017v4
  13. Start date: Jun 2017 to Aug 2017v3
  14. Start date: Apr 2017 to Jun 2017v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
Trial Details
NCT Number NCT03079999
Lead Sponsor Massachusetts Eye and Ear Infirmary
Collaborators: United States Department of Defense
Conditions
(from sponsor)		 Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
Related terms Neurofibromatosis 2, Neuroma, Acoustic
Enrollment 97 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov